To summarize, we propose a conceptual framework, informed by experience with AL and AA amyloidosis as well as preliminary data in ATTRv-PN amyloidosis, suggesting that a greater magnitude and consistency of reduction in serum TTR concentration will lead to better clinical outcomes in patients with ATTR-CM (Figure 3). This evidence concerns the gene TTR and axial length measurement.